4.3 Article

Complete Radiological Response of Colorectal Liver Metastases after Chemotherapy: What Can We Expect?

期刊

DIGESTIVE SURGERY
卷 28, 期 2, 页码 114-120

出版社

KARGER
DOI: 10.1159/000323820

关键词

Missing metastasis; Disappearing metastasis; Complete pathological response; Colorectal cancer; Liver metastasis; Chemotherapy; Hepatic intra-arterial chemotherapy

资金

  1. European Society of Surgical Oncology (ESSO)
  2. Association Francaise de Chirurgie Hepato-Biliaire et de Transplantation Hepatique (ACHBT)

向作者/读者索取更多资源

Missing metastases, also called vanishing or disappearing liver metastases, concern about 5% of patients with colorectal liver metastasis undergoing chemotherapy, and this phenomenon is likely to become more frequent in the near future, with the widespread use of highly efficient chemotherapy. As their definition is highly dependent on the quality of initial imaging, a DLM on preoperative computed tomography scan should be systematically confirmed by a second imaging modality, ideally magnetic resonance imaging. It is important to note that a complete clinical response does not mean a complete pathologic response. Currently, there are no absolute criteria of a complete pathologic response. However, treatment with neoadjuvant and adjuvant hepatic arterial infusion in patients < 60 years old with an initially low carcinoembryonic antigen level that normalizes under chemotherapy and who have no detectable lesion on both computed tomography and magnetic resonance imaging is probably more likely to yield a complete pathologic response. Whatever their treatment, patients with DLM run a high risk of recurrence that could be decreased with the use of HAI. Despite a high recurrence rate, the overall 5-year survival rate of patients with DLM ranges from 40 to 80%. Having a DLM should no longer be a contraindication to hepatic surgery since long-term survival is expected in these highly chemosensitive patients. The use of adjuvant HAI in addition to efficient systemic chemotherapy could reduce the risk of hepatic relapse. Copyright (C) 2011 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Surgery of resectable local recurrence following colorectal cancer: Compartmental surgery improves local control

Frederic Dumont, Cecile Loaec, Romuald Wernert, Blandine Maurel, Emilie Thibaudeau, Laurence Vilcot

Summary: This study aimed to identify prognostic factors and determine the optimal extent of surgery for local recurrence following colorectal cancer. The results showed that complete compartmental surgery is safe and improves local control.

JOURNAL OF SURGICAL ONCOLOGY (2022)

Article Oncology

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

Zhenggang Ren, Michel Ducreux, Ghassan K. Abou-Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assenat, Sheng Hu, Lorenza Rimassa, Tao Zhang, Jean-Frederic Blanc, Hongming Pan, Paul Ross, Chia-Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming-Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque, Ann-Lii Cheng

Summary: Tislelizumab demonstrated durable antitumor activity and acceptable tolerability in previously treated advanced HCC patients, regardless of the number of prior lines of therapy.

LIVER CANCER (2023)

Article Oncology

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab

Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng

Summary: The IMbrave150 trial showed that atezolizumab + bevacizumab is safe and effective in treating patients with hepatocellular carcinoma, including those with hepatitis B or hepatitis C infection.

LIVER CANCER (2023)

Article Oncology

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study

Masatoshi Kudo, Richard S. S. Finn, Peter R. R. Galle, Andrew X. X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni

Summary: The study demonstrates the efficacy and safety of atezolizumab + bevacizumab treatment in patients with baseline BCLC Stage B hepatocellular carcinoma, consistent with the overall study population.

LIVER CANCER (2023)

Article Oncology

Delaying Surgery After Neoadjuvant Chemotherapy Affects Survival in Patients with Colorectal Peritoneal Metastases: A BIG-RENAPE Network Multicentric Study

Frederic Dumont, Vahan Kepenekian, Valeria De Franco, Clarisse Eveno, Patrick Rat, Charles Sabbagh, Jean-Jacques Tuech, Jean-Marc Bereder, Maxime Gerard, Cecile Loaec, Elodie Martin, Loic Campion, Olivier Glehen

Summary: Multimodal treatment, including perioperative chemotherapy and complete resection, improves survival in patients with peritoneal metastases from colorectal cancer. However, the impact of treatment delays on oncologic outcomes remains uncertain.

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Gastroenterology & Hepatology

Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series

Youssef Mahdi, Mouna Khmou, Amine Souadka, Hajar El Agouri, Soumaya Ech-charif, Chaimaa Mounjid, Basma El Khannoussi

Summary: This study reports the largest analysis of NRAS and KRAS status in colorectal metastatic patients in North Africa. The study found that KRAS mutations occurred in approximately 51.7% of tumors, mainly in exon 12, while NRAS mutations were found in only 3% of tumors. The study also found a significant correlation between NRAS mutations and age.

BMC GASTROENTEROLOGY (2023)

Letter Oncology

Beyond surgical excellence: Unveiling the role of intensive rehabilitation in RIOT for CRS and HIPEC

Amine Souadka, Brahim El Ahmadi

JOURNAL OF SURGICAL ONCOLOGY (2023)

Article Oncology

Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel

Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.

LIVER CANCER (2023)

Review Oncology

Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy

Raefa Abou Khouzam, Jean-Marie Lehn, Hemma Mayr, Pierre-Alain Clavien, Michael Bradley Wallace, Michel Ducreux, Perparim Limani, Salem Chouaib

Summary: Hypoxia is a crucial characteristic of the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) and plays a significant role in its pathogenesis. This review focuses on the impact of hypoxia on genomic instability and the tumor immune microenvironment in PDAC. Strategies for alleviating hypoxia and their potential applications for diagnosis and therapy in PDAC patients will also be discussed.

CANCERS (2023)

Letter Oncology

Striking a balance: Deciphering the dilemma of treatment equivalence in cardia gastric cancer

Mohammed Oussama Louafi, Oumayma Lahnaoui, Amine Benkabbou, Mohammed Anass Majbar, Raouf Mohsine, Basma El Khannoussi, Saber Boutayeb, Amine Souadka

JOURNAL OF SURGICAL ONCOLOGY (2023)

Article Oncology

From burden to relief: The economic and quality-of-life advantages of pseudo continent perineal colostomy in ultra-low rectal cancer patients

Oumayma Lahnaoui, Hajar Essangri, Nezha El Bahaoui, Mohammed Anass Majbar, Amine Benkabbou, Raouf Mohsine, Amine Souadka

Summary: In ULRC patients, PCPC is a cost-effective alternative to the standard definitive colostomy without alteration of the QOL or additional perineal complications during the first 6 months following the surgery.

JOURNAL OF SURGICAL ONCOLOGY (2023)

Article Oncology

Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind

Paul Matte, Michel Ducreux

Summary: This article reports a case of a patient with low rectal cancer who experienced vision loss 3 weeks after starting treatment with capecitabine and radiotherapy. After ruling out other possible diagnoses, toxicity of the antineoplastic agent is considered the most likely hypothesis, making it the first case of vision loss induced by capecitabine.

CASE REPORTS IN ONCOLOGY (2023)

Article Surgery

The learning curve of laparoscopic rectal cancer surgery of millennial surgeons: Lessons for a safe implementation in low- and middle-income countries

Hamza Sekkat, Amine Souadka, Leila Alaoui, Ali Rafik, Zakaria Belkhadir, Laila Amrani, Amine Benkabbou, Raouf Mohsine, Anass Mohammed Majbar

Summary: This study aimed to analyze the learning curve of two millennial surgeons during the implementation of the first laparoscopic rectal cancer surgery program in a low- and middle-income country cancer center. The study found that both surgeons had a safe and short learning curve in terms of operative duration and conversion to open surgery.

JOURNAL OF MINIMAL ACCESS SURGERY (2023)

Letter Oncology

Elevating standards: A comprehensive model for peritoneal surface malignancy management in developing healthcare systems

Amine Souadka, Saber Boutayeb, Basma El Khannoussi, Hanane El Kacimi, Oumayma Lahnaoui, Amine Benkabbou, Mohammed Anass Majbar, Abdelilah Ghannam, Zakaria Houssain Belkhadir, Raouf Mohsine, Brahim El Ahmadi

JOURNAL OF SURGICAL ONCOLOGY (2023)

Meeting Abstract Surgery

854 The Establishment of a National Peritoneal Surface Malignancy Programme: The Success, Pitfalls and Difficulties of the Moroccan Experience

Hajar Essangri, Nezha El Bahaoui, Abdelilah Souadka, Mohammed Anass Majbar, Amine Benkabbou, Raouf Mohsine, Amine Souadka

BRITISH JOURNAL OF SURGERY (2022)

暂无数据